In particular, 93% of pancreatic ductal adenocarcinoma and 52% of colorectal cancers, those most prevalent in the AMPLIFY-201 study, are positive for KRAS mutations.

Source: https://forextv.com/top-news/elicio-therapeutics-presents-updated-preliminary-immunogenicity-data-from-the-ongoing-phase-1-study-of-eli-002-and-new-preclinical-data-on-eli-007-and-eli-008-at-the-society-for-immunotherapy-of-cance/

In the ongoing study, the original three cohorts included patients with non-small cell lung cancer, EGFR wild type, gastric and gastroesophageal junction adenocarcinoma and pancreatic hepatocellular and biliary tract cancers respectively.

Source: https://seekingalpha.com/article/4651686-affimed-n-v-afmd-q3-2023-earnings-call-transcript?source=feed_all_articles